Editor's Note :

close editor's note Editor's Note :

We're currently hosting a symposium on Tuesday's decision in Espinoza v. Montana Department of Revenue. Click to follow along.
We also hosted a symposium on Monday's decision in June Medical Services v. Russo. Click to read the submissions.

Briefly Mentioned :

Briefly Noted :

On Thursday, the court released orders from the July 1 conference. The justices granted five cases for a total of four hours of oral argument next term.
On Monday, we expect the court to release opinions at 10 a.m. We will be live-blogging starting at 9:20 a.m. at this link, where you can sign up for an email reminder when the live blog begins.

Actavis, Inc. v. Demahy

Consolidated with:

Docket No. Op. Below Argument Opinion Vote Author Term
09-1501 5th Cir. Mar 30, 2011
Tr.
Jun 23, 2011 5-4 Thomas OT 2010

Holding: Federal drug regulations applicable to generic drug manufacturers directly conflict with, and thus preempt, state-law tort claims alleging a failure to provide adequate warning labels.

Judgment: Reversed, 5-4, in an opinion by Justice Clarence Thomas on June 23, 2011. The Chief Justice and Justices Scalia and Alito joined the opinion in full, while Justice Kennedy joined as to all but Part III-B-2. Justice Sotomayor filed a dissenting opinion, which was joined by Justices Ginsburg, Breyer, and Kagan.

SCOTUSblog Coverage

Briefs and Documents

Merits Briefs

Amicus Briefs

Certiorari-stage documents

 
Share:
Term Snapshot
At a Glance
Awards